FTM
First Turn Management Portfolio holdings
AUM
$536M
This Quarter Return
+41.3%
1 Year Return
+36.36%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$696M
AUM Growth
–
Cap. Flow
+$696M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.25%
Holding
31
New
31
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Cytokinetics
CYTK
|
$67.4M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$35.4M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$33.2M |
| 4 |
argenx
ARGX
|
$31.7M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$31.3M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cytokinetics
CYTK
$4.23B
| $67.4M | 9.68% |
+807,444
| New | +$67.4M |
|
|
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
| $35.4M | 5.08% |
+1,497,331
| New | +$35.4M |
|
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $33.2M | 4.77% |
+81,683
| New | +$33.2M |
|
|
4
argenx
ARGX
$43.6B
| $31.7M | 4.56% |
+83,403
| New | +$31.7M |
|
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $31.3M | 4.5% |
+680,389
| New | +$31.3M |
|
6
Krystal Biotech
KRYS
$4.27B
| $30M | 4.31% |
+242,185
| New | +$30M |
|
7
Legend Biotech
LEGN
$6.41B
| $28.6M | 4.11% |
+476,079
| New | +$28.6M |
|
|
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $27.7M | 3.97% |
+87,369
| New | +$27.7M |
|
9
Transmedics
TMDX
$3.92B
| $25.5M | 3.66% |
+323,185
| New | +$25.5M |
|
10
Insulet
PODD
$23.9B
| $25M | 3.59% |
+115,366
| New | +$25M |
|
11
Day One Biopharmaceuticals
DAWN
$769M
| $24.8M | 3.57% |
+1,700,949
| New | +$24.8M |
|
12
Mirum Pharmaceuticals
MIRM
$3.71B
| $24.7M | 3.55% |
+836,302
| New | +$24.7M |
|
|
VRNA
13
Verona Pharma
VRNA
$9.16B
| $24M | 3.44% |
+1,206,291
| New | +$24M |
|
14
DexCom
DXCM
$29.5B
| $23.9M | 3.44% |
+192,932
| New | +$23.9M |
|
15
Axsome Therapeutics
AXSM
$6.05B
| $23.5M | 3.38% |
+295,428
| New | +$23.5M |
|
16
Immunocore
IMCR
$1.62B
| $23.4M | 3.37% |
+343,079
| New | +$23.4M |
|
17
Vaxcyte
PCVX
$4B
| $22.5M | 3.22% |
+357,528
| New | +$22.5M |
|
18
Immunovant
IMVT
$2.56B
| $21.6M | 3.1% |
+512,893
| New | +$21.6M |
|
19
Biohaven
BHVN
$1.63B
| $20.4M | 2.93% |
+477,314
| New | +$20.4M |
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $19.7M | 2.82% |
+203,882
| New | +$19.7M |
|
21
Ascendis Pharma
ASND
$11.8B
| $19.1M | 2.74% |
+151,587
| New | +$19.1M |
|
22
Nuvalent
NUVL
$5.52B
| $18.8M | 2.7% |
+255,897
| New | +$18.8M |
|
23
Ionis Pharmaceuticals
IONS
$6.79B
| $18M | 2.59% |
+356,679
| New | +$18M |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.6M | 2.24% |
+217,425
| New | +$15.6M |
|
25
Roivant Sciences
ROIV
$8.15B
| $15.3M | 2.2% |
+1,363,504
| New | +$15.3M |
|